Vasoactive Intestinal Peptide (VIP) Research: What 14,310 Studies Show (2026) | RetatrutideCompare

Vasoactive Intestinal Peptide (VIP) — 14,310 studies indexed on PubMed. Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation. Half-life: ~2 minutes (rapidly degraded). FDA status: Not FDA-approved (analog in research).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Vasoactive Intestinal Peptide (VIP)?

There are approximately 14,310 studies indexed on PubMed that mention Vasoactive Intestinal Peptide (VIP) (VIP-28), based on a search last updated 2026-06-18.

Is Vasoactive Intestinal Peptide (VIP) FDA-approved?

FDA status: Not FDA-approved (analog in research).

How does Vasoactive Intestinal Peptide (VIP) work?

Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.

Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.

Reference facts

Also known as
VIP-28
Category
Gastrointestinal
Mechanism of action
Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.
Targets
VPAC1, VPAC2
Indications under research or approved
Research — sarcoidosis (analog Aviptadil, RLF-100, COVID respiratory failure)
Regulatory status (reference entry)
Not FDA-approved (analog in research)
Half-life
~2 minutes (rapidly degraded)
Sequence
HSDAVFTDNYTRLRKQMAVKKYLNSILN
Sequence notes
28-residue peptide of the secretin/glucagon family.
Molecular weight (Da)
3326
First reported
1970

Primary References

Explore research articles about Vasoactive Intestinal Peptide (VIP)

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.